Novo Nordisk and Sangamo BioSciences Announce Agreement
Novo Nordisk A/S and Sangamo BioSciences, Inc. have announced an agreement that provides Novo Nordisk with access to Sangamo's proprietary zinc finger DNA-binding protein (ZFP) technology.
Sangamo will provide its ZFP technology for Novo Nordisk to evaluate for use in the field of enhanced protein production.
"Novo Nordisk recognizes the need for innovative technologies that aid in the rapid development of novel therapies to combat disease," said Esper Boel, Vice-President and Head of Biotechnology of Novo Nordisk.
"We look forward to evaluating Sangamo's proprietary technology for enhanced protein production."
"We are very pleased to be able to provide Novo Nordisk, the world leader in diabetes care, with our ZFP technology," said Edward Lanphier, Sangamo's president and chief executive officer.
"We have engineered ZFP transcription factors that can significantly increase production from genes expressing protein pharmaceuticals and we can engineer zinc finger nucleases (ZFNs™) to facilitate the efficient generation of production cell lines with altered traits.”
“With the increased approval and demand for protein pharmaceuticals, we believe that our technology has an important place in modern drug development."